J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF95.00.

Key Insights The considerable ownership by individual investors in Novartis indicates that they collectively have ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation.

The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...

Learn more about whether Corcept Therapeutics Incorporated or Novartis AG is a better investment based on AAII's A+ Investor ...

Novartis AG (NYSE:NVS – Get Free Report) has received an average recommendation of “Reduce” from the ten analysts that are currently covering the company, Marketbeat reports. Three analysts ...

Piyush Goyal, the usually affable union minister of commerce and industry, has stirred a hornet’s nest with his comments ...

CBLL's lockup expiration on April 9th could impact share prices. Click here to find out why CBLL stock is a Sell.

Alnylam Pharmaceuticals, Inc.’s ALNY share price has dipped by 10.08%, which has investors questioning if this is right time ...